Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $20

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $25 to $20.
byBenzinga Newsdesk
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $25 to $20.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts